Product Pipeline

A New View of Cancer Diagnostics


Cernostics’ lead product under development, TissueCypher™ Barrett’s Esophagus Assay, uses whole slide digital imaging technology to produce comprehensive risk prediction for the development of esophageal cancer in patients with Barrett’s Esophagus.  The TissueCypher™ Barrett’s Esophagus Assay will focus on eliminating uncertainty related to the treatment of Barrett’s Esophagus and will provide actionable information to doctors and patients.


In addition to our lead product, Cernostics continues to evaluate clinical indications for which the TissueCypher™ platform can provide actionable clinical information.  Examples of this ongoing work are provided below for lung, colon, and breast cancer.  Roll over the images below to see the difference that TissueCypher™ can provide for whole slide image analysis.


Roll over to see what TissueCypher™ sees when viewing lung cancer, colon cancer, and breast cancer tissues.

lung-cancer lung-cancer-revealed
Lung Adenocarcinoma labeled with a nuclear dye (blue), macrophage marker (green) and inflammation biomarkers (red and yellow). Macrophages can be quantified, phenotyped and their spatial relationships with cancer cells can be measured.
colon-cancer colon-cancer-revealed
Colon Adenocarcinoma labeled with a nuclear dye (blue), an epithelial cell marker (orange) and a proliferation marker (green). Proliferating cells can be detected and quantified in both the epithelial compartment and in the stroma.
breast-cancer breast-cancer-revealed
Breast Ductal Carcinoma labeled with a nuclear dye (blue), tumor cell marker (red) and a proliferation marker (green). Proliferating tumor cells can be detected within the tumor nests and proliferating immune cells are seen throughout the stroma.



Learn more about our intellectual property and patents.

Customer Service

Mon-Fri 9am-5pm (EST)